Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 46, Issue 5, 2008, Pages 608-611

  Marcobal, Angela ^a   Underwood, Mark A ^a   Mills, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bifidobacteria; Lactobacilli; Probiotics; Terminal restriction fragment length polymorphism

Indexed keywords

PROBIOTIC AGENT; BACTERIAL RNA; RNA 16S;

ARTICLE; BACTERIAL COUNT; BACTERIUM IDENTIFICATION; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS HELVETICUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; LACTOCOCCUS LACTIS; MICROBIAL COMMUNITY; MICROBIAL IDENTIFICATION; NONHUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPECIES DIFFERENCE; STREPTOCOCCUS THERMOPHILUS; VALIDATION PROCESS; BACILLUS; BIFIDOBACTERIUM; CHEMISTRY; CLASSIFICATION; DIET SUPPLEMENTATION; FOOD PACKAGING; GENETICS; ISOLATION AND PURIFICATION; LACTOBACILLUS; STANDARD;

BACTERIA (MICROORGANISMS);

BACILLUS; BIFIDOBACTERIUM; DIETARY SUPPLEMENTS; FOOD LABELING; LACTOBACILLUS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROBIOTICS; RNA, BACTERIAL; RNA, RIBOSOMAL, 16S; SPECIES SPECIFICITY;

EID: 48249085783     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181660694     Document Type: Article

References (21)

1. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol 2007; 119:184-91.
2. Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotis-ing enterocolitis in preterm neonates with very low birth weight: a systematic review of randomised controlled trials. Lancet 2007; 369:1614-20.
3. Canani R, Cirillo P, Terrin G, et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007;335:340.
4. Hedin C, Whelan K, Lindsay J. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007;66:307-15.
5. Szajewska H, Fordymacka A, Bardwski J, et al. Microbiological and genetic analysis of probiotic products licensed for medicinal purposes. Med Sci Monit 2004;10:346-50.
6. Theunissen J, Britz TJ, Torriani S, et al. Identification of probiotic microorganisms in South African products using PCR-based DGGE analysis. Int J Food Microbiol 2005;98:11-21.
7. Marsh TL. Terminal restriction fragment length polymorphism (T-RFLP): an emerging method for characterizing diversity among homologous populations of amplification products. Curr Opin Microbiol 1999;2:323-7.
8. Sakamoto M, Hayashi H, Benno Y. Terminal restriction fragment length polymorphism analysis for human fecal microbiota and its application for analysis of complex bifidobacterial communities. Microb Inmunol 2003;47:133-42.
9. Marsh TL, Saxman P, Cole J, et al. Terminal restriction fragment length polymorphism analysis program, a web-based research tool for microbial community analysis. Appl Environ Microbiol 2002; 66:695-700.
10. Clement BG, Kehl LE, DeBord KL, et al. Terminal restriction fragment patterns (T-RFLP), a rapid PCR-based method for the comparison of complex bacterial communities. J Microbiol Methods 1998;31:135-42.
11. Matsuki T, Watanabe K, Tanaka R, et al. Rapid identification of human intestinal bifidobacteria by 16S rRNA-targeted species and group-specific primers. FEMS Microbiol Lett 1998;167:113-21.
12. Matsuki T, Watanabe K, Tanaka R, et al. Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-gene-targeted species-specific primers. Appl Environ Microbiol 1999;65:4506-12.
13. Walter J, Tannock GW, Tilsala-Timisjarvi A, et al. Detection and identification of gastrointestinal Lactobacillus species by using denaturing gradient gel electrophoresis and species-specific PCR primers. Appl Environ Microbiol 2000;66:297-303.
14. Saito Y, Sakamoto M, Takizawa S, et al. Monitoring the cell number and viability of Lactobacillus helveticus gcllOOl in human feces by PCR methods. FEMS Microbiol Lett 2004;231:125.
15. Byun R, Nadkarni MA, Chhour KL, et al. Quantitative analysis of diverse Lactobacillus species present in advanced dental caries. J Clin Microbiol 2004;42:3128-36.
16. Klocke M, Mundt K, Idler C, et al. Monitoring Lactobacillus plantarum in grass silages with the aid of 16S rDNA-based quantitative real-time PCR assays. Syst Appl Microbiol 2006;29:49-58.
17. Lick S, Drescher K, Heller KJ. Survival of Lactobacillus delbrueck-ii subsp. bulgaricus and Streptococcus thermophilus in the terminal ileum of fistulated Gottingen minipigs. Appl Environ Microbiol 2001;67:4137-43.
18. Pu ZY, Dobos M, Limsowtin GKY, et al. Integrated polymerase chain reaction-based procedures for the detection and identification of species and subspecies of the gram-positive bacterial genus Lactococcus. J Appl Microbiol 2002;93:353-61.
19. Fasoli S, Marzotto M, Rizzotti L, et al. Bacterial composition of commercial probiotic products as evaluated by PCR-DGGE analysis. Int J Food Microbiol 2003;82:59-70.
20. Matsumoto M, Sakamoto M, Hayashi H, et al. Novel phylogenetic assignment database for terminal-restriction fragment length polymorphism analysis of human colonic microbiota. J Microbiol Meth 2005;61:305-19.
21. Canganella F, Paganini S, Ovidi M, et al. A microbial investigation on probiotic pharmaceutical products used for human health. Microbiol Res 1997;152:171-9.